We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
Read MoreHide Full Article
Inogen Inc. (INGN - Free Report) is set to report fourth-quarter 2017 results on Feb 27, after the market closes.
In the last quarter, the company reported adjusted earnings of 33 cents per share, which beat the Zacks Consensus Estimate of 29 cents and the year-ago quarter’s figure of 16 cents. The upside was driven by roughly 26.8% growth in revenues, which totaled $69.0 million and beat the Zacks Consensus Estimate of almost $64.0 million.
An expanding long-term oxygen therapy market, inherent benefits of portable oxygen concentrators (POC) over traditional delivery model, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key catalysts. The stock delivered positive earnings surprise in each of the trailing four quarters, the average beat being 16%.
Let’s take a look at how things are shaping up prior to the second-quarter earnings announcement.
Inogen’s expanding product portfolio is a key catalyst. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, One G4 is a single-solution portable oxygen concentrator. The platform has been driving sales over the past few quarters. The trend is expected to continue in the upcoming quarterly results.
Further, Inogen One G3 portable oxygen concentrator brings mobility and independence to oxygen therapy users.
Coming to the next important platform in the company’s product portfolio, Inogen At Home is aptly formulated for patients who need oxygen therapy during sleep. This group is estimated to represent more than 30% of the total oxygen patient base in the United States.
Continuing with the slew of product developments and launches, the company received EC Certificate for One G4, recently. This development is expected to enhance productivity across sales, billing and customer service teams.
Here is what our quantitative model predicts:
Our proven model shows that Inogen is likely to beat estimates this quarter. This is because a stock needs to have a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Inogen has an Earnings ESP of +25.3%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Inogen carries a Zacks Rank #2.
Other Stocks to Consider
Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Exelixis (EXEL - Free Report) has an Earnings ESP of +8.94% and a Zacks Rank #2.
Amphastar Pharmaceuticals (AMPH - Free Report) has an Earnings ESP of +264.71% and a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Is a Beat in Store for Inogen (INGN) This Earnings Season?
Inogen Inc. (INGN - Free Report) is set to report fourth-quarter 2017 results on Feb 27, after the market closes.
In the last quarter, the company reported adjusted earnings of 33 cents per share, which beat the Zacks Consensus Estimate of 29 cents and the year-ago quarter’s figure of 16 cents. The upside was driven by roughly 26.8% growth in revenues, which totaled $69.0 million and beat the Zacks Consensus Estimate of almost $64.0 million.
An expanding long-term oxygen therapy market, inherent benefits of portable oxygen concentrators (POC) over traditional delivery model, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key catalysts. The stock delivered positive earnings surprise in each of the trailing four quarters, the average beat being 16%.
Inogen, Inc Price and Consensus
Inogen, Inc Price and Consensus | Inogen, Inc Quote
Let’s take a look at how things are shaping up prior to the second-quarter earnings announcement.
Inogen’s expanding product portfolio is a key catalyst. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, One G4 is a single-solution portable oxygen concentrator. The platform has been driving sales over the past few quarters. The trend is expected to continue in the upcoming quarterly results.
Further, Inogen One G3 portable oxygen concentrator brings mobility and independence to oxygen therapy users.
Coming to the next important platform in the company’s product portfolio, Inogen At Home is aptly formulated for patients who need oxygen therapy during sleep. This group is estimated to represent more than 30% of the total oxygen patient base in the United States.
Continuing with the slew of product developments and launches, the company received EC Certificate for One G4, recently. This development is expected to enhance productivity across sales, billing and customer service teams.
Here is what our quantitative model predicts:
Our proven model shows that Inogen is likely to beat estimates this quarter. This is because a stock needs to have a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Inogen has an Earnings ESP of +25.3%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Inogen carries a Zacks Rank #2.
Other Stocks to Consider
Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Universal Health Services (UHS - Free Report) has an Earnings ESP of +1.96% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis (EXEL - Free Report) has an Earnings ESP of +8.94% and a Zacks Rank #2.
Amphastar Pharmaceuticals (AMPH - Free Report) has an Earnings ESP of +264.71% and a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>